Core Viewpoint - The announcement highlights the acceptance of the new drug application (NDA) for the influenza treatment drug, Madaxin (玛氘诺沙韦颗粒), by the National Medical Products Administration (NMPA) in China, marking a significant milestone as it is the first innovative antiviral drug targeting influenza in children to complete Phase III clinical trials and apply for market approval in China [1] Group 1: Drug Details - Madaxin is a cap-dependent endonuclease inhibitor that works by inhibiting the replication of the influenza virus, blocking the transcription of the virus's own mRNA, thereby precisely suppressing viral replication [1] - Clinical studies indicate that Madaxin shows good safety in pediatric patients, faster symptom relief and viral clearance, lower risk of resistance, oral efficacy unaffected by food, and a dosage form more suitable for pediatric patients [1]
先声药业：玛氘诺沙韦颗粒新药上市申请(NDA)获国家药品监督管理局受理